Cerus Blood-Safety System Passes Late-Stage Trial, Raising Hopes for Safer Red Blood Cell Transfusions

CONCORD, Calif. — Cerus Corporation said on Monday, November 2, 2026, that its INTERCEPT Blood System for red blood cells met the main goal of a late-stage clinical trial, showing that pathogen-reduced red blood cells performed comparably to conventional red blood cells in patients who needed transfusions. Reuters reported the result the same day, and Cerus announced the topline findings in a company statement.

The trial, known as RedeS, tested whether red blood cells treated with Cerus's pathogen-reduction technology could raise patients' hemoglobin levels as effectively as untreated donor red blood cells. Hemoglobin is the protein in red blood cells that carries oxygen around the body, and the change in hemoglobin after a transfusion is a standard way to judge whether a transfusion worked.

On the trial's primary measure, the treated blood was non-inferior to conventional blood — that is, it was not worse by more than a preset margin. Cerus reported an adjusted hemoglobin increment of 1.996 grams per deciliter in the INTERCEPT arm, based on 195 patients, compared with 2.050 grams per deciliter in the control arm, based on 199 patients. The estimated difference was minus 0.054 grams per deciliter, with a 95 percent confidence interval from minus 0.210 to 0.103. Because the lower bound of that interval stayed above the prespecified non-inferiority margin of minus 0.32 grams per deciliter, the trial met its primary endpoint, with a p-value of 0.004.

On safety, Cerus reported no statistically significant difference in treatment-related adverse events between the two arms. Treatment-emergent adverse events possibly, probably or definitely related to a study transfusion were reported in 3.4 percent of the INTERCEPT arm (9 of 267 patients) compared with 2.5 percent of the control arm (7 of 276 patients), a difference that was not statistically significant (p = 0.634).

The company also reported that a small number of patients developed temporary, low-titer, treatment-emergent antibodies specific to the INTERCEPT treatment. Cerus said there was no evidence of hemolysis — the destruction of red blood cells — and no clinical impact was detected, and that the finding was consistent with its earlier ReCePI study.

Illustration: A donated blood bag and transfusion equipment in a hospital setting.

What Happened

Cerus, a biotechnology company based in Concord, California and listed on Nasdaq under the ticker CERS, announced positive topline results from the Phase 3 RedeS trial (NCT03037164) on November 2, 2026. Reuters covered the announcement the same day, summarizing the headline finding: red blood cells treated with the company's INTERCEPT technology performed as well as conventional red blood cells in patients requiring transfusions.

The INTERCEPT Blood System for red blood cells is designed to reduce the risk of viruses, bacteria and other pathogens in donated blood products, according to Cerus and Reuters. Pathogen reduction is an extra safety step applied to donated blood components before transfusion, intended to inactivate a broad range of infectious agents that might otherwise slip through donor screening and testing.

Importantly, the announcement is a topline result, not a regulatory approval. Cerus was explicit on that point: the INTERCEPT Blood System for red blood cells remains investigational in the United States and has not been approved by the U.S. Food and Drug Administration (FDA). The company also said the FDA has not yet reviewed the final RedeS clinical study report, and that the agency's assessment of the findings and the overall benefit-risk profile may differ from Cerus's assessment.

Cerus said it would discuss the results on a conference call on the afternoon of November 2, alongside its third-quarter 2026 financial results, with a replay available on the company's website through November 23, 2026.

Background: Why Blood Safety Still Needs New Tools

Modern blood donation already involves careful donor screening and laboratory testing, and transfusion is a routine, life-saving part of care for surgery, trauma, cancer treatment, anemia and many other conditions. But no screening system can catch every threat, every time — particularly newly emerging pathogens, or infections in their earliest window before tests can detect them.

That gap is the reason pathogen-reduction technologies exist. Rather than testing for one pathogen at a time, they aim to inactivate a wide range of viruses, bacteria and parasites in the donated component itself. If the approach works without damaging the blood cells, it could add a layer of protection that does not depend on knowing exactly which pathogen to look for.

Red blood cells are the most commonly transfused blood component, which makes them an important test case. Platelets and plasma treated with pathogen-reduction systems are already in use in some settings, but extending the approach to red blood cells has been a longer scientific road, because red cells must survive storage, circulate after transfusion, and carry oxygen effectively — all while tolerating the treatment process.

Cerus's RedeS trial is the latest in a sequence of late-stage studies of its red blood cell system. The company noted that the antibody finding in RedeS was consistent with its prior ReCePI study, an earlier Phase 3 trial in a different patient group. The RedeS topline numbers therefore build on, rather than stand alone from, that earlier work — though full, peer-reviewed publication of the RedeS data will be needed before independent experts can judge the results in full.

Illustration: A scientist studies treated red blood cells in a research laboratory.

Why It Matters

For patients, the most immediate question is simple: does treated blood work as well as ordinary blood? The RedeS topline answer, on the trial's chosen measure, is yes — within the preset margin. The adjusted hemoglobin increments in the two arms were close (1.996 versus 2.050 grams per deciliter), and the statistical test for non-inferiority passed comfortably against the minus 0.32 margin.

For blood services, the result matters because safety and supply are linked. A pathogen-reduction step that preserves red cell function could, if approved, help blood centers respond more quickly to emerging infectious threats, rather than waiting for a specific test to be developed, validated and rolled out. It could also reduce reliance on deferring donors or discarding units when a new risk appears.

For clinicians, the safety data will draw close attention. The reported rates of treatment-related adverse events were low in both arms and not significantly different, and the antibody finding — temporary, low-titer antibodies with no sign of hemolysis or clinical effect — will need to be weighed in the full study report and in any regulatory review. Antibodies that target transfused cells can matter in repeat transfusion, so regulators and hematologists will want the detailed immunology data, not just the topline summary.

For investors and the wider biotechnology sector, the result removes one major uncertainty around Cerus's red blood cell program, while leaving the decisive question — regulatory approval — unanswered. The company's own statement stresses that the topline results do not establish approval or its timing, a caution that applies to every investigational therapy at this stage.

What Happens Next

The next steps are regulatory and scientific rather than commercial. The FDA has not yet reviewed the final RedeS clinical study report, so a formal regulatory submission and review would still lie ahead, along with any questions the agency raises about the full dataset, manufacturing, and longer-term safety.

Independent scrutiny will also matter. Topline announcements give headline numbers; the full study report and any peer-reviewed publication will let outside researchers check the trial design, the patient groups, subgroup results, and the antibody data in detail. Until then, the RedeS result should be read as encouraging early evidence from the sponsor, not as a settled verdict from regulators or the wider scientific community.

Blood centers and hospitals will also watch practical questions: how the treatment fits into existing collection, processing and storage workflows, what it costs per unit, and how it performs in the patients who need transfusions most often, including people who receive repeated transfusions over months or years.

If those hurdles are cleared, pathogen-reduced red blood cells could become another layer in the safety net that already protects transfusion recipients. If they are not, RedeS will still have added a substantial dataset — hundreds of patients across its efficacy and safety analyses — to a field where the safety bar for a product given to millions of people is, rightly, very high.

This article is general information only and is not medical advice; the therapy described here is investigational and has not been approved.

Illustration: A patient receives a blood transfusion while a nurse monitors the procedure.

Sponsored: explore today's featured sponsored offers

FAQ

What is the INTERCEPT Blood System for red blood cells?

It is Cerus's pathogen-reduction technology for donated red blood cells, designed to reduce the risk of viruses, bacteria and other pathogens in blood products before transfusion. In the United States it remains investigational and is not FDA-approved.

What did the Phase 3 RedeS trial find?

The trial met its primary endpoint: INTERCEPT-treated red blood cells were non-inferior to conventional red blood cells by adjusted hemoglobin increment, with 1.996 grams per deciliter in the treated arm versus 2.050 in the control arm, and the confidence interval staying above the preset minus 0.32 margin.

Was the treated blood as safe as conventional blood in the trial?

On the reported topline safety measure, yes in statistical terms: treatment-related adverse events were 3.4 percent in the INTERCEPT arm and 2.5 percent in the control arm, with no statistically significant difference. A small number of patients developed temporary, low-titer antibodies with no evidence of hemolysis or clinical impact, according to Cerus.

Does this mean the product is now approved?

No. Cerus states that the FDA has not yet reviewed the final RedeS study report, that the product remains investigational in the United States, and that the topline results do not establish approval or its timing.

Why does pathogen reduction matter if donor blood is already tested?

Screening and testing catch known threats, but they cannot always detect new or emerging pathogens, or infections in their earliest window. Pathogen reduction aims to inactivate a broad range of agents in the blood component itself, adding a layer of protection that does not depend on a specific test.

Sources

• Reuters, “Cerus' blood-safety system meets main goal in late-stage trial,” 2 November 2026.
• Cerus Corporation, press release via Business Wire, “Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells,” 2 November 2026.
• RedeS trial registration, ClinicalTrials.gov NCT03037164, as cited in Cerus's 2 November 2026 announcement.